|1.||Follo, M Y: 2 articles (05/2012 - 02/2011)|
|2.||Mongiorgi, S: 2 articles (05/2012 - 02/2011)|
|3.||Finelli, C: 2 articles (05/2012 - 02/2011)|
|4.||Cocco, L: 2 articles (05/2012 - 02/2011)|
|5.||Martelli, A M: 2 articles (05/2012 - 02/2011)|
|6.||Clissa, C: 2 articles (05/2012 - 02/2011)|
|7.||Piazzi, M: 1 article (05/2012)|
|8.||Filì, C: 1 article (05/2012)|
|9.||Colombi, C: 1 article (05/2012)|
|10.||Manzoli, L: 1 article (05/2012)|
12/01/2000 - "CD24 modified by sialylLex was required on the tumor cells because the LPS-induced lung arrest was abolished by removal of CD24 from the cell surface by phosphatidylinositol-specific phospholipase C. "
05/01/1989 - "It is proposed that a phosphatidylinositol-specific phospholipase C (PLC) enzyme may be present in abnormally high concentrations in certain cancer cells, and that the elevated activity may explain many, if not all, of the neoplastic characteristics of the cancer cells. "
01/30/1990 - "Phosphoinositide phospholipase C activity was investigated in human melanoma grown as solid tumor xenografts in nude mice. "
10/01/1993 - "Release of carcinoembryonic antigen from human tumor cells by phosphatidylinositol-specific phospholipase C: highly effective extraction and upregulation from LS-174T colonic adenocarcinoma cells."
10/01/1993 - "Carcinoembryonic antigen (CEA), produced by gastrointestinal tumor cells, is anchored to cell membrane by a glycosyl-phosphatidylinositol moiety which can be cleaved with phosphatidylinositol-specific phospholipase C (PI-PLC). "
|2.||Hypertension (High Blood Pressure)
02/01/1990 - "The present study revealed an increase of Ca2(+)-stimulated IP3 release in SHR, suggesting high polyphosphoinositide phosphodiesterase activity in this model of hypertension."
07/01/1987 - "These studies demonstrate that a phosphatidylinositol-specific phospholipase C-prostaglandin synthetic system may play an important role in the course of hypertension in SHRSP."
09/01/1990 - "These data demonstrated that protein kinase C and membrane-bound PIP2-PLC are altered during the period of hypertension development. "
|3.||Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria)
06/15/1990 - "In this study we demonstrate that, as with Fc gamma RIIINK, Fc gamma RIIIM phi is resistant to the action of phosphatidylinositol-specific phospholipase C and is expressed at normal levels on affected (glycosylphosphatidylinositol-anchor negative) cultured monocytes from patients with paroxysmal nocturnal hemoglobinuria. "
03/01/1995 - "Monocytes treated with phosphoinositol-specific phospholipase C and monocytes from patients with paroxysmal nocturnal hemoglobinuria, lacking the phosphatidylinositol-anchored CD14, did not respond to LPS stimulation with O2- production. "
09/01/1989 - "CD59 antigen was released from the surface of transfected COS cells by phosphatidylinositol-specific phospholipase C, demonstrating that it is attached to the cell membrane by means of a glycolipid anchor; it is therefore likely to be absent from the surface of affected erythrocytes in the disease paroxysmal nocturnal hemoglobinuria."
08/15/1989 - "That is, K/NK lymphocyte Fc gamma RIII was resistant to phosphatidylinositol-specific phospholipase C and surface expression of Fc gamma RIII was not affected on K/NK lymphocytes from patients with paroxysmal nocturnal hemoglobinuria, a disorder of hemopoietic stem cells resulting in deficient expression of glycan-phosphatidylinositol-anchored proteins. "
|4.||Hepatocellular Carcinoma (Hepatoma)
06/15/1988 - "These data, taken together, are consistent with a glycan structure for this autocrine factor, which bears strong resemblance to similar insulinomimetic factors generated in BC3H1 myocytes and H-35 hepatoma cells in response to insulin and on digestion of membranes with a phosphatidylinositol-specific phospholipase C. "
01/01/1987 - "A major glycoprotein of rat hepatoma plasma membranes was selectively released as a soluble form by incubating the membrane with phosphatidylinositol-specific phospholipase C. "
09/15/1992 - "We applied this procedure to two of the cell types used in these studies, H4IIE hepatoma cells and isolated hepatocytes, but were unable to detect a [3H]glucosamine-containing lipid that met any of the criteria for GPIs, including sensitivity to phosphatidylinositol-specific phospholipase C (PIPLC) or GPI-specific phospholipase D. "
01/01/1987 - "The results indicate that the glycoprotein of rat hepatoma plasma membranes, which has an unusually high content of carbohydrate, is another membrane protein released by phosphatidylinositol-specific phospholipase C, as documented for alkaline phosphatase, acetylcholinesterase and Thy-1 antigen."
07/12/1990 - "In the present study, membranes prepared from HL-60 promyelocytic leukemia cells were used to examine the mechanism by which these ATP receptors activate phosphatidylinositol-specific phospholipase C (PI-PLC) under defined in vitro conditions. "
03/15/1994 - "A putative protein tyrosine phosphatase inhibitor, phenylarsine oxide (PAO), potentiated phospholipase D (PLD) activity concentration-dependently in [3H] oleic acid-labeled rat basophilic leukemia (RBL-2H3) cells without significant increase in phosphatidylinositol-specific phospholipase C (PI-PLC) activity. "
|2.||Phospholipases A2 (Phospholipase A2)
|3.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
|5.||phosphatidylcholine-specific phospholipase C
|7.||Immunoglobulin G (IgG)
|9.||Purinergic P2 Receptors (ADP Receptor)
|10.||Tranexamic Acid (AMCA)
|2.||Heterologous Transplantation (Xenotransplantation)